The food allergy specialist just landed its first approval.
News & Analysis: Aimmune Therapeutics
The FDA’s approval sets the company off on the right path as it advances in the treatment of food allergies.
The first approved drug for any food allergy may be the first of several from Aimmune Therapeutics.
An upcoming FDA decision on Aimmune’s first drug could set the tone for the rest of its pipeline.
With FDA approval deadlines approaching in 2020, these four drug developers could see substantial gains if they're successful.
Big gains could be just a click of the buy button away.
AIMT earnings call for the period ending September 30, 2019.
A survey of allergists suggests Palforzia's launch could be more successful than expected.
How vaping risks may impact cannabis companies and Aimmune Therapeutics' plan to change how doctors treat peanut allergies.
Here's what a benign briefing document means, and what it doesn't.